title: Polymorphic OCT1: a valid biomarker, but for which drugs?
authors.affiliation: Institute of Clinical Pharmacology, University Medical Center, Georg-August-University Göttingen, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. jbrockm@gwdg.de.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Brockmöller
authors.forename: Mladen V
authors.initials: MV
authors.lastname: Tzvetkov
mesh_terms: D054316:Biomarkers, Pharmacological; D002412:Cations; D006801:Humans; D008687:Metformin / Q000737:chemistry / Q000627:therapeutic use; D009020:Morphine / Q000737:chemistry / Q000627:therapeutic use; D009536:Niacinamide / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D027702:Organic Cation Transporter 1 / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics*; D010597:Pharmacogenetics; D010671:Phenylurea Compounds / Q000737:chemistry / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D054316:Biomarkers, Pharmacological; D002412:Cations; D027702:Organic Cation Transporter 1; D010671:Phenylurea Compounds; D009536:Niacinamide; D009020:Morphine; D008687:Metformin; D000077157:Sorafenib